Teva Expects To Carve Out Sizable Niche For Uzedy In Antipsychotic Market
Long-Acting Injectable Adds To Franchise
Uzedy was recently approved by the US FDA as an extended-release subcutaneous formula of risperidone; it is poised to be a new prong in Teva’s branded portfolio.
